Benchling is tasked with migrating Sanofi's R&D into the digital era
Benchling, a leading provider of R&D cloud software for the biotech industry, has partnered with Sanofi to transition over 1,500 scientists to Benchling's digital R&D Cloud platform, enabling Sanofi to aggregate complex data, accelerate research processes, and harness AI across the R&D lifecycle.
Benchling recently announced that pharmaceutical and healthcare giant Sanofi is leveraging Benchling's cloud platform across more than 1,500 scientists from 30 teams. This is a momentous partnership for Benchling, a company that serves many leading biotechnology startups, plus over half of the top 50 global biopharma companies. The company's cloud platform offers over 200,000 scientists a centralized hub of truth for scientific data, analysis, and collaboration.
As Sanofi readies itself to unlock a new era in biotechnology, Benchling will collaborate with Sanofi to transition its legacy R&D workflows to a digital platform hosted in the Benchling R&D Cloud. With this move, Sanofi's R&D teams will scale and accelerate months-long research processes to complete them in a few hours. Benchling's cloud will be used across the full R&D lifecycle at Sanofi for early workflows including precision oncology, core therapeutic pipeline teams working on novel modalities like mRNA, and translational teams. Benchling R&D Cloud aggregates complex data from Sanofi's different departments, unlocking improved decision-making, analytics, and collaboration across Sanofi's research departments.
Sajith Wickramasekara, Benchling's CEO and co-founder commented on the company's collaboration with Sanofi: "Sanofi's adoption of Benchling unlocks their ability to harness AI. With our R&D Cloud, their scientists can accelerate timelines for life-changing medicines."
